<DOC>
	<DOC>NCT01764321</DOC>
	<brief_summary>This prospective, post marketing, observational, Noninterventional Study (NIS) is designed to compare drug persistence in patients treated with Certolizumab Pegol (CZP) and patients treated with any other subcutaneously (sc) administered Tumor Necrosis Factor (TNF) inhibitor.</brief_summary>
	<brief_title>Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosis of Rheumatoid Arthritis (RA) Moderate to severe disease activity of RA The patient receives Tumor Necrosis Factor (TNF) inhibitor in combination with at least 1 synthetic Disease Modifying Antirheumatic Drug (DMARD) The decision to prescribe a TNF inhibitor in combination with DMARD is made by the treating physician, prior to and independently from the decision to include the patient in this NonInterventional Study (NIS) Male or female patients ≥ 18 years of age, considered by the treating physician to be reliable and capable of adhering to the observational plan (eg, able to understand and complete questionnaires) The patient personally signed and dated Patient Data Consent Form (PDCF) prior to Visit 2 Treatment is according to the Summary of Product Characteristics (SmPC) Known contraindications to Tumor Necrosis Factor (TNF) inhibitors Prior use of any TNF inhibitors (including Adalimumab, Etanercept, Infliximab, Certolizumab, or Golimumab), or other biologic DMARDs (including Abatacept, Rituximab, Tocilizumab, or Anakinra) Participation in an investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia®</keyword>
	<keyword>TNF inhibitor</keyword>
	<keyword>DMARD</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>